Avenacy Announces Launch of Eptifibatide for Injection in the U.S. Market
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Eptifibatide for Injection in the United States as a therapeutic equivalent generic for Integrilin® for Injection (Eptifibatide) approved by the U.S. Food and Drug Administration.
- Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Eptifibatide for Injection in the United States as a therapeutic equivalent generic for Integrilin® for Injection (Eptifibatide) approved by the U.S. Food and Drug Administration.
- Eptifibatide for Injection is indicated for use in acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI).
- View the full release here: https://www.businesswire.com/news/home/20240429526438/en/
Avenacy’s Eptifibatide for Injection is available as a 75 mg/100 mL single-dose vial. - Avenacy will begin shipping Eptifibatide for Injection to wholesale partners this week.